|
|
Volumn 84, Issue 5 A, 1999, Pages 26-31
|
|
Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
CELL SURFACE RECEPTOR;
DALTEPARIN;
ENOXAPARIN;
FIBRINOGEN RECEPTOR;
GLYCOPROTEIN RECEPTOR GPIB IX;
GLYCOPROTEIN RECEPTOR GPIB-IX;
HEPARIN;
LOW MOLECULAR WEIGHT HEPARIN;
THROMBIN RECEPTOR;
ANTICOAGULANT THERAPY;
CLINICAL TRIAL;
DRUG ANTAGONISM;
HEART INFARCTION;
HEART MUSCLE ISCHEMIA;
HUMAN;
METABOLISM;
REGISTER;
REVIEW;
RISK;
SUDDEN DEATH;
TREATMENT OUTCOME;
UNSTABLE ANGINA PECTORIS;
ANGINA, UNSTABLE;
ANTICOAGULANTS;
CLINICAL TRIALS;
DALTEPARIN;
DEATH, SUDDEN, CARDIAC;
ENOXAPARIN;
HEPARIN;
HEPARIN, LOW-MOLECULAR-WEIGHT;
HIRUDIN THERAPY;
HUMANS;
MYOCARDIAL INFARCTION;
MYOCARDIAL ISCHEMIA;
PLATELET GLYCOPROTEIN GPIB-IX COMPLEX;
PLATELET MEMBRANE GLYCOPROTEINS;
RECEPTORS, CELL SURFACE;
REGISTRIES;
RISK;
TREATMENT OUTCOME;
|
|
EID: 0033517243
PISSN: 00029149
EISSN: None
Source Type: Journal
DOI: 10.1016/S0002-9149(99)00380-X Document Type: Article |
|
Times cited : (17)
|
|
References (18)
|
